SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

ampreloxetine

TBPH·Theravance Biopharma, Inc.
BEARISH
Drug Impact Rating0/10
Trial phase
Phase 3 (failed)
Time to market
Not applicable. The drug failed all Phase 3 trials and development has been terminated.
Why 0/10
No upcoming catalysts exist for ampreloxetine. The drug failed its pivotal Phase 3 CYPRESS study in March 2026, Theravance was acquired by Zymeworks and delisted in September 2026, and the program has been effectively terminated. ImpactScore is 0 because the developer no longer exists as a public company and the drug has no active development path.
Actionable Insight BEARISH

Ampreloxetine is a failed drug with no active development program. Theravance Biopharma (TBPH) was acquired by Zymeworks (ZYME) in a deal that closed September 2026, and TBPH shares were delisted. There are no upcoming catalysts for this drug. For investors, the relevant surviving public company is Zymeworks (ZYME), which acquired Theravance primarily for its commercial YUPELRI respiratory asset, not for ampreloxetine.

Price Chart

Loading chart...

Executive Summary

Ampreloxetine (TD-9855) was Theravance Biopharma's investigational once-daily norepinephrine reuptake inhibitor for symptomatic neurogenic orthostatic hypotension (nOH). The drug failed three consecutive Phase 3 trials: SEQUOIA (2021), REDWOOD (2022), and the pivotal CYPRESS study in MSA patients (March 2026). The CYPRESS failure triggered a 50% workforce reduction and a strategic review that led to Theravance's acquisition by Zymeworks for $929 million. The acquisition closed in September 2026, TBPH was delisted, and ampreloxetine development has been effectively terminated. There is no publicly traded stock tied to this drug's development anymore.

How It Works

Ampreloxetine is a norepinephrine reuptake inhibitor, meaning it increases levels of the neurotransmitter norepinephrine in the body. This helps raise blood pressure by improving the constriction of blood vessels. It was being studied as a once-daily pill for neurogenic orthostatic hypotension (nOH), a condition where the nervous system fails to regulate blood pressure properly, causing dangerous drops when a person stands up.

Trial Status

Ampreloxetine completed three Phase 3 trials: Study 0169 (SEQUOIA, topline September 2021) and Study 0170 (REDWOOD, topline April 2022) both failed in mixed nOH populations. The third Phase 3 trial, CYPRESS (NCT05696717), specifically in nOH due to multiple system atrophy (MSA), failed its primary endpoint in March 2026. Detailed CYPRESS data were presented in August 2026. No further trials are planned.

The Two-Sided Case

▲ Bull Case3
The drug had Orphan Drug Designation from the FDA for nOH in MSA patients, reflecting an unmet medical need.
Theravance continued to present new analyses at medical conferences even after the initial Phase 3 failures, suggesting some investigators saw signals worth exploring.
The acquisition by Zymeworks at $17/share provided a floor for TBPH shareholders after the CYPRESS failure sent the stock lower.
▼ Bear Case4
Ampreloxetine failed all three Phase 3 trials it entered (SEQUOIA in 2021, REDWOOD in 2022, CYPRESS in March 2026), none meeting their primary endpoints.
The CYPRESS failure in MSA patients triggered a 50% workforce reduction and the end of Theravance's internal R&D, making further development of ampreloxetine highly unlikely.
Theravance Biopharma was acquired by Zymeworks and delisted from Nasdaq on September 24, 2026. TBPH shares no longer trade publicly.
Analysts downgraded TBPH en masse after the CYPRESS failure, with HC Wainwright cutting to Neutral and B. Riley to Neutral.

Upcoming Catalysts

  • None. The drug program has been terminated and the developer acquired and delisted.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Theravance Biopharma, Inc. 8-K TBPH ·Originating report

Sources · 8

Hover a chip for the title
1 theglobeandmail.com2 bioworld.com3 markets.businessinsider.com4 nasdaq.com5 prnewswire.com6 nasdaq.com7 msn.com8 msn.com